skip to Main Content

FDA Grants Orphan Drug Designation to Pancreatic Cancer Drug, ASH Meeting Highlights — Top Stories in Hematology/Oncology

FDA Grants Orphan Drug Designation to Pancreatic Cancer Drug, ASH Meeting Highlights — Top Stories in Hematology/Oncology
The FDA granting orphan drug designation to a pancreatic cancer product was one of the top stories in hematology and oncology last week.

Healio’s continuing coverage of the American Society of Hematology’s annual meeting made up some of the other top stories. These included data that suggested efgartigimod (argenx) was effective in primary immune thrombocytopenia and that mosunetuzumab (Genentech) induced remissions in advanced non-Hodgkin lymphoma. Read more . . . 


Back To Top